Attention Deficit Hyperactivity Disorder

Neurology·MeSH: Attention Deficit Disorder with Hyperactivity

15 drugs in development·11 companies·4 clinical trials

Drug Pipeline by Phase

Approved(12)

Drug	Company
Cotempla XR-ODT	AYTU BIOPHARMA, INC (AYTU)
dextroamp saccharate	ELITE PHARMACEUTICALS INC /NV/ (ELTP)
dextroamp saccharate	ANI PHARMACEUTICALS INC (ANIP)
focalin xr	Societal CDMO, Inc. (SCTL)
guanfacine	Aptinyx Inc. (APTX)
guanfacine	SUNSET ISLAND GROUP (SUN)
guanfacine	GH Research PLC (GHRS)
Jornay PM	COLLEGIUM PHARMACEUTICAL, INC (COLL)
lisdexamfetamine di	Amneal Pharmaceuticals, Inc. (AMRX)
lisdexamfetamine di	ELITE PHARMACEUTICALS INC /NV/ (ELTP)
lisdexamfetamine di	Mylan II B.V. (MYL)
ritalin la	Societal CDMO, Inc. (SCTL)

Phase 4(3)

BioSniper tracks 15 drugs in development for Attention Deficit Hyperactivity Disorder across 11 companies.

There are 4 clinical trials targeting Attention Deficit Hyperactivity Disorder tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.